Skip to main
DNLI
DNLI logo

Denali Therapeutics (DNLI) Stock Forecast & Price Target

Denali Therapeutics (DNLI) Analyst Ratings

Based on 12 analyst ratings
Strong Buy
Strong Buy 58%
Buy 42%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Denali Therapeutics Inc demonstrates a promising financial outlook, with revenue projections for its TIVI product expected to rise from $8 million in 2026 to $433 million by FY30. The company's management has expressed confidence in the potential for TIVI to receive accelerated approval for MPS II by the specified PDUFA date, which could significantly enhance the company's commercial prospects. Additionally, the anticipated advantages of the DNL310 product over the current competitive offerings further solidify the positive sentiment surrounding Denali's pipeline developments.

Bears say

Denali Therapeutics is projected to generate significantly lower revenues, estimating only $8 million in 2026, compared to the consensus estimate of $44 million, indicating potential concerns regarding market demand and product viability. The company's capacity to advance its development programs is jeopardized by a failure to raise capital, which may hinder timely completion of critical projects. Additional risks include competitive pressures from other firms, potential regulatory delays, and challenges related to manufacturing and scaling operations, all of which could negatively impact the company's financial performance and stock outlook.

Denali Therapeutics (DNLI) has been analyzed by 12 analysts, with a consensus rating of Strong Buy. 58% of analysts recommend a Strong Buy, 42% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Denali Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Denali Therapeutics (DNLI) Forecast

Analysts have given Denali Therapeutics (DNLI) a Strong Buy based on their latest research and market trends.

According to 12 analysts, Denali Therapeutics (DNLI) has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Denali Therapeutics (DNLI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.